View Archive

1st Annual European Congress on Immunotherapies in Cancer™

1st Annual European Congress on Immunotherapies in Cancer™

23-24 September 2016
W Barcelona
Barcelona, Spain


The clinical development of immunotherapies is undoubtedly one of the hottest areas in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. In addition to landmark data on the integration of new strategies into evolving treatment paradigms, preclinical and clinical data continue to rapidly accumulate on immunotherapy basic science.

However, the rapidity of the changes in the field and information that continues to emerge create practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy evidence on immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.

The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide a comprehensive review of key data sets that are most relevant for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on science advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancer.

2016 Can't-Miss Topics

  • State-of-the-art immunotherapy: basic science updates
  • Checkpoint blockade: Where are we now? Where are we going?
  • Updates in clinical immunotherapy across tumor types (lung, head and neck, melanoma, lymphoma, breast, gynecological, gastrointestinal, and genitourinary) 
  • Practical challenges in expanding and commercializing immunotherapy platforms
  • Integrating available immunotherapeutics into standard approaches
  • Modulating the tumor-microenvironment-immune system interface
  • Finding synergy: immunotherapy-containing combination therapy
  • Incorporating biomarkers into trials versus practice
  • Overcoming resistance


Program Chair
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA

Roman Perez-Soler, MD 
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, New York, USA

European Planning Committee
Joan Carles, MD, PhD
Associate Professor of Medicine. UIC
Director GU, CNS and Sarcoma Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain
Enriqueta Felip, MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain
Jose A Lopez-Martin, MD, PhD
Chairman, GETICA (Grupo Español de Terapias Inmuno-Biologicas en Cancer / Spanish Group for Cancer Immuno-Biotherapy)
Early Clinical and Translational Research Unit
Sarcoma & Melanoma Programme
Medical Oncology Department,
'12 de Octubre' University Hospital
Madrid, Spain
Aleix Prat, MD, PhD
Head of the Medical Oncology Department
Hospital Clinic
Associate Professor
University of Barcelona
Head of the Translational Genomics Group
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Joaquim Bellmunt, MD, PhD
Director, Bladder Cancer Center
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts, USA
Dr. Thomas Blankenstein
Research Group Leader, Max-Delbrück-Center for Molecular Medicine (MDC)
Director, Institute for Immunology, Charité – Universitätsmedizin
Berlin, Germany
George Coukos, MD, PhD
Director, Lausanne Branch
Ludwig Institute for Cancer Research
Lausanne, Switzerland
Alena Gros, PhD
Group Leader, Tumor Immunology and Immunotherapy Group
Vall d'Hebron Institute of Oncology (V.H.I.O.)
Barcelona, Spain
John B.A.G. Haanen, MD, PhD
Head of the Division of Medical Oncology and
Staff Scientist in the Division of Immunology
The Netherlands Cancer Institute
Amsterdam, Netherlands
Professor of Translational Immunotherapy of Cancer
Leiden University Medical Center
Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Department of Pathology and Laboratory Medicine
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania, USA
Ronald Levy, MD
Division of Oncology
Stanford School of Medicine
Stanford, California, USA
David F. McDermott, MD
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program
Director, Biologic Therapy and Cutaneous Oncology Programs, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts, USA
Sergio Quezada, PhD
Group Leader, Immune Regulation and Tumor Immunotherapy Lab
University College London Cancer Institute
London, United Kingdom
Caroline Robert, MD, PhD
Head of the Dermatology Unit, Department of Medicine
Gustave Roussy and Paris Sud University
Villejuif Grand-Paris, France
Jacob Schachter, MD
Head – The Ella Lemelbaum Institute for Melanoma
Division of Oncology
Sheba Medical Center
Tel Hashomer, Israel
Peter Schmid, FRCP, MD, PhD
Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute, Queen Mary University of London
Director, Barts Breast Centre, Barts Hospital London
London, United Kingdom
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Vall d' Hebron University Hospital
Vall d'Hebron Institute of Oncology (V.H.I.O.)
Barcelona, Spain

Target Audience

This educational activity is intended for healthcare professionals based outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain mechanistic approaches toward targeting the immune system to treat cancer
  • Evaluate the clinical applicability of data from clinical trials of immunotherapy strategies
  • Discuss methods to individualize the use of immunotherapy strategies, including the use of biomarkers
  • Describe how to proactively mitigate and manage adverse events associated with the use of treatment strategies used in the care of patients with cancer
  • Identify unmet clinical needs in cancer treatment and highly anticipated clinical trials evaluating novel immunotherapeutic approaches


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By